PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30352091-8	2018	Among patients with GAS infections, clindamycin administered concomitantly with a beta-lactam within 24 hours of admission decreased mortality (AOR: 0.04, 95%CI: 0.003-0.55, P = 0.02.	Clindamycin	36-47	gastrin	Homo sapiens	20-23
30352091-14	2018	Adjunctive clindamycin reduced mortality in invasive GAS infections; immunoglobulins did not, but power was limited.	Clindamycin	11-22	gastrin	Homo sapiens	53-56
30352091-15	2018	The highest mortality was seen in patients with GAS pneumonia/empyema, for whom clindamycin was protective but underused.	Clindamycin	80-91	gastrin	Homo sapiens	48-51
28592549-11	2017	Among the 102 tested strains, 100 (98%) were mupA positive and 97 (95%) were fusB positive, 26/27 clindamycin-resistant strains (96.3%) were ermA positive, 83 strains (81.4%) were lukS/lukF positive, 95 (93%) carried both eta and etb genes, and 99 (97%) were fnbA positive.	Clindamycin	98-109	rRNA methylase Erm(A)	Staphylococcus aureus	141-145
29725709-5	2018	Enrofloxacin, ciprofloxacin, tilmicosin, sulfadiazine, ampicillin and clindamycin were classified as the substrates of chicken P-gp according to the rules suggested by FDA, as their net efflux ratios were greater than two.	Clindamycin	70-81	phosphoglycolate phosphatase	Gallus gallus	127-131
29725709-6	2018	Similarly, enrofloxacin, ciprofloxacin, tilmicosin, florfenicol, ampicillin and clindamycin were classified as the substrates of BCRP.	Clindamycin	80-91	ATP binding cassette subfamily G member 2	Canis lupus familiaris	129-133
29725709-7	2018	Among these drugs, enrofloxacin, ciprofloxacin, tilmicosin, ampicillin, and clindamycin were the cosubstrates of P-gp and BCRP, however, chicken BCRP and P-gp exhibit different affinities to the shared substrates at different concentrations by blocking either one or both transport with specific inhibitors in the coexpression system.	Clindamycin	76-87	phosphoglycolate phosphatase	Gallus gallus	113-117
29725709-7	2018	Among these drugs, enrofloxacin, ciprofloxacin, tilmicosin, ampicillin, and clindamycin were the cosubstrates of P-gp and BCRP, however, chicken BCRP and P-gp exhibit different affinities to the shared substrates at different concentrations by blocking either one or both transport with specific inhibitors in the coexpression system.	Clindamycin	76-87	ATP binding cassette subfamily G member 2	Canis lupus familiaris	122-126
29725709-7	2018	Among these drugs, enrofloxacin, ciprofloxacin, tilmicosin, ampicillin, and clindamycin were the cosubstrates of P-gp and BCRP, however, chicken BCRP and P-gp exhibit different affinities to the shared substrates at different concentrations by blocking either one or both transport with specific inhibitors in the coexpression system.	Clindamycin	76-87	ATP binding cassette subfamily G member 2	Canis lupus familiaris	145-149
29725709-7	2018	Among these drugs, enrofloxacin, ciprofloxacin, tilmicosin, ampicillin, and clindamycin were the cosubstrates of P-gp and BCRP, however, chicken BCRP and P-gp exhibit different affinities to the shared substrates at different concentrations by blocking either one or both transport with specific inhibitors in the coexpression system.	Clindamycin	76-87	phosphoglycolate phosphatase	Gallus gallus	154-158
29408609-11	2018	Depletion of secondary bile acid-producing bacteria with antibiotics that kill anaerobic bacteria (clindamycin) promoted C jejuni-induced colitis in specific pathogen-free Il10-/- mice compared with the nonspecific antibiotic nalidixic acid; colitis induction by antibiotics was associated with reduced level of luminal deoxycholate.	Clindamycin	99-110	interleukin 10	Mus musculus	172-176
27527109-0	2017	HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions.	Clindamycin	40-51	major histocompatibility complex, class I, B	Homo sapiens	0-5
27527109-6	2017	We found 6 out of 12 clindamycin-induced cADR patients carried HLA-B*51:01, and all of them received clindamycin via intravenous drip (6/9).	Clindamycin	21-32	major histocompatibility complex, class I, B	Homo sapiens	63-68
27527109-7	2017	The carrier frequency of HLA-B*51:01 is significantly higher compared with the control group (P=0.0006; OR=9.731, 95% CI: 2.927-32.353) and the clindamycin-tolerant group (OR=24.000, 95% CI: 3.247-177.405).	Clindamycin	144-155	major histocompatibility complex, class I, B	Homo sapiens	25-30
27527109-8	2017	In silico docking showed clindamycin is potentially more stable inside HLA-B*51:01 protein.	Clindamycin	25-36	major histocompatibility complex, class I, B	Homo sapiens	71-76
27527109-9	2017	Our results suggested, for the first time, that HLA-B*51:01 is a risk allele for clindamycin-related cADRs in Han Chinese, especially when clindamycin is administered via intravenous drip.	Clindamycin	81-92	major histocompatibility complex, class I, B	Homo sapiens	48-53
27527109-9	2017	Our results suggested, for the first time, that HLA-B*51:01 is a risk allele for clindamycin-related cADRs in Han Chinese, especially when clindamycin is administered via intravenous drip.	Clindamycin	139-150	major histocompatibility complex, class I, B	Homo sapiens	48-53
28495631-1	2017	We report the synthesis of Ag2S-Chitosan nanocomposites and Ag2S-chitosan nanohybrids as performance adsorbents for Lincosamides such as Clindamycin antibiotic removal.	Clindamycin	137-148	angiotensin II receptor type 1	Homo sapiens	27-31
28495631-1	2017	We report the synthesis of Ag2S-Chitosan nanocomposites and Ag2S-chitosan nanohybrids as performance adsorbents for Lincosamides such as Clindamycin antibiotic removal.	Clindamycin	137-148	angiotensin II receptor type 1	Homo sapiens	60-64
28495631-5	2017	In particular, Ag2S-Chitosan nanocomposites and Ag2S-chitosan nanohybrids show high maximum Clindamycin adsorption capacity (qmax) of 153.21, and 181.28mgg-1, respectively.	Clindamycin	92-103	angiotensin II receptor type 1	Homo sapiens	15-19
28495631-5	2017	In particular, Ag2S-Chitosan nanocomposites and Ag2S-chitosan nanohybrids show high maximum Clindamycin adsorption capacity (qmax) of 153.21, and 181.28mgg-1, respectively.	Clindamycin	92-103	angiotensin II receptor type 1	Homo sapiens	48-52
28495631-6	2017	More strikingly, Ag2S-Chitosan nanocomposites and Ag2S-chitosan nanohybrids are also demonstrated to nearly completely remove Clindamycin from drinking water.	Clindamycin	126-137	angiotensin II receptor type 1	Homo sapiens	17-21
28495631-6	2017	More strikingly, Ag2S-Chitosan nanocomposites and Ag2S-chitosan nanohybrids are also demonstrated to nearly completely remove Clindamycin from drinking water.	Clindamycin	126-137	angiotensin II receptor type 1	Homo sapiens	50-54
27793493-7	2016	Metronidazole or clindamycin is effective to treat BV (EL3).	Clindamycin	17-28	spectrin beta, erythrocytic	Homo sapiens	55-58
27998243-6	2017	Quantitative polymerase chain reaction analysis demonstrated that clindamycin treatment restores inflammatory cytokine and growth factor expression to the same levels as the no inoculation/no antibiotic group, demonstrating that clindamycin can ameliorate the negative effects of bacterial inoculation and does not itself negatively impact the expression of important cytokines.	Clindamycin	66-77	myotrophin	Rattus norvegicus	123-136
27998243-6	2017	Quantitative polymerase chain reaction analysis demonstrated that clindamycin treatment restores inflammatory cytokine and growth factor expression to the same levels as the no inoculation/no antibiotic group, demonstrating that clindamycin can ameliorate the negative effects of bacterial inoculation and does not itself negatively impact the expression of important cytokines.	Clindamycin	229-240	myotrophin	Rattus norvegicus	123-136
27626604-6	2017	Given that the minimum effective serum concentration of clindamycin is 0.3 microg/mL, a dose interval of 60 h could be achieved for each tested ERF.	Clindamycin	56-67	ETS2 repressor factor	Canis lupus familiaris	144-147
27626604-8	2017	The treatment of dogs with either ERF may provide several benefits over treatment with clindamycin alone.	Clindamycin	87-98	ETS2 repressor factor	Canis lupus familiaris	34-37
26430943-9	2015	RESULTS: In 300 samples, the susceptibility rates of GAS to penicillin, erythromycin, azithromycin, clindamycin, and tetracycline in northern Israel still remain very high.	Clindamycin	100-111	gastrin	Homo sapiens	53-56
26320398-11	2016	Compared with vancomycin-susceptible S. aureus, hVISA and VISA isolates were less susceptible to ciprofloxacin, clindamycin, daptomycin, gentamicin, rifampin, and trimethoprim/sulfamethoxazole, and are thus, more likely to have SCCmec II or III element.	Clindamycin	112-123	mitochondrial antiviral signaling protein	Homo sapiens	48-53
26320398-11	2016	Compared with vancomycin-susceptible S. aureus, hVISA and VISA isolates were less susceptible to ciprofloxacin, clindamycin, daptomycin, gentamicin, rifampin, and trimethoprim/sulfamethoxazole, and are thus, more likely to have SCCmec II or III element.	Clindamycin	112-123	mitochondrial antiviral signaling protein	Homo sapiens	49-53
27845497-7	2016	The co-administration of rhLys and clindamycin or metronidazole improved both antibiotics" efficiency and lysozyme-driven biofilm degradation.	Clindamycin	35-46	lysozyme	Homo sapiens	106-114
26691681-11	2016	An over-representation of resistance solely to clindamycin was associated with the unusual lsaC gene and serotype III ST19/rib lineage (p <0.001).	Clindamycin	47-58	cyclin dependent kinase 2 associated protein 1	Homo sapiens	118-122
26266120-7	2015	Those isolates which showed inducible clindamycin resistance were randomly selected and subjected to PCR for the observation of erm A and erm C genes.	Clindamycin	38-49	rRNA methylase Erm(A)	Staphylococcus aureus	128-133
26266120-7	2015	Those isolates which showed inducible clindamycin resistance were randomly selected and subjected to PCR for the observation of erm A and erm C genes.	Clindamycin	38-49	ErmC	Staphylococcus aureus	138-143
26266120-11	2015	Inducible clindamycin was mainly due to presence of erm A gene.	Clindamycin	10-21	rRNA methylase Erm(A)	Staphylococcus aureus	52-57
25444568-8	2014	MRSA-CC1 strains showed higher percentages of erythromycin/clindamycin resistance (95%/89%) than MRSA-CC398 strains (58%/63%), and this resistance was usually mediated by erm(C) gene.	Clindamycin	59-70	C-C motif chemokine ligand 14	Homo sapiens	5-8
25493020-3	2014	WT and IL-10(-/-) mice (n = 20 each) were exposed to an antibiotic cocktail for three days and then were injected with clindamycin (i.p.).	Clindamycin	119-130	interleukin 10	Mus musculus	7-12
24567842-9	2014	Penicillin (7%), erythromycin (28%), ceftriaxone (10%), and clindamycin (10%) nonsusceptibility were commonly identified, concentrated among a small number of serotypes (including 19A, 35B, 15B/C, and 15A).	Clindamycin	60-71	SLAM family member 7	Homo sapiens	180-183
27025750-5	2014	Real-time PCR analysis revealed that ciprofloxacin and clindamycin reduce butyrate-induced transcription of the human cathelicidin LL-37 in the colonic epithelial cell line HT-29.	Clindamycin	55-66	cathelicidin antimicrobial peptide	Homo sapiens	131-136
23806146-10	2013	The toxin genes sec, seh, and enterotoxin gene cluster (egc) were significantly more prevalent among isolates of lineage ST9 (p<0.001) compared to other lineages, and the ST9 isolates were more resistant to erythromycin, clindamycin, ciprofloxacin, chloramphenicol, and gentamicin.	Clindamycin	224-235	Enterotoxin	Staphylococcus aureus	30-41
24008826-11	2014	CONCLUSIONS: Compared with previous surveys, little evolution was seen in susceptibility, except a decline in activity of clindamycin against Prevotella spp.	Clindamycin	122-133	histocompatibility minor 13	Homo sapiens	153-156
23097003-0	2013	Interaction of dihydrofolate reductase and aminoglycoside adenyltransferase enzyme from Klebsiella pneumoniae multidrug resistant strain DF12SA with clindamycin: a molecular modelling and docking study.	Clindamycin	149-160	dihydrofolate reductase	Klebsiella pneumoniae	15-38
23861873-9	2013	3D models of the most prevalent variants of beta-lactamases namely TEM-1, SHV-1, OXA-1, and ESBL namely CTX-M-15 were predicted and docking was performed with clindamycin and piperacillin-tazobactam to reveal the molecular basis of drug sensitivity.	Clindamycin	159-170	hypothetical protein	Escherichia coli	67-72
23861873-9	2013	3D models of the most prevalent variants of beta-lactamases namely TEM-1, SHV-1, OXA-1, and ESBL namely CTX-M-15 were predicted and docking was performed with clindamycin and piperacillin-tazobactam to reveal the molecular basis of drug sensitivity.	Clindamycin	159-170	beta-lactamase OXA-1 precursor	Escherichia coli	81-86
23614804-6	2013	Polymerase chain reaction results demonstrated that all constitutive and inducible clindamycin resistant strains contained only the ermC gene.	Clindamycin	83-94	ErmC	Staphylococcus aureus	132-136
23580915-8	2013	Patient was successfully treated 4 weeks with oral clindamycin 300 mg bid.	Clindamycin	51-62	BH3 interacting domain death agonist	Homo sapiens	70-73
23097003-0	2013	Interaction of dihydrofolate reductase and aminoglycoside adenyltransferase enzyme from Klebsiella pneumoniae multidrug resistant strain DF12SA with clindamycin: a molecular modelling and docking study.	Clindamycin	149-160	aminoglycoside adenyltransferase	Klebsiella pneumoniae	43-75
23097003-11	2013	Clindamycin was found to be suitable inhibitor of DHFR and AadA.	Clindamycin	0-11	dihydrofolate reductase	Klebsiella pneumoniae	50-54
23097003-11	2013	Clindamycin was found to be suitable inhibitor of DHFR and AadA.	Clindamycin	0-11	aminoglycoside adenyltransferase	Klebsiella pneumoniae	59-63
23478252-10	2013	Compared to placebo, coinfected mice treated with linezolid, vancomycin or clindamycin had decreased pulmonary IL-6 and mKC at 4 hours and IFN-gamma at 24 hours after MRSA coinfection (all P<0.05).	Clindamycin	75-86	interleukin 6	Mus musculus	111-115
23478252-10	2013	Compared to placebo, coinfected mice treated with linezolid, vancomycin or clindamycin had decreased pulmonary IL-6 and mKC at 4 hours and IFN-gamma at 24 hours after MRSA coinfection (all P<0.05).	Clindamycin	75-86	interferon gamma	Mus musculus	139-148
22921930-8	2012	Clindamycin administration was associated with a lower risk for CDI due to BI/NAP1/027 when compared to non-BI/NAP1/027 CDI (OR 0.24, 95% CI 0.12-0.48).	Clindamycin	0-11	nucleosome assembly protein 1 like 1	Homo sapiens	78-82
22921930-11	2012	Clindamycin was associated with a lower risk of CDI due to BI/NAP1/027.	Clindamycin	0-11	nucleosome assembly protein 1 like 1	Homo sapiens	62-66
22760047-11	2012	ileS2 was detected in 81 of 82 phenotypically highly mupirocin-resistant strains and associated with resistance to ciprofloxacin, erythromycin, and clindamycin.	Clindamycin	148-159	isoleucyl-tRNA synthetase	Staphylococcus aureus	0-5
20842069-14	2010	CONCLUSIONS: Most cases of childhood AHOM can be treated for 20 days, including a short period intravenously, with large doses of a well-absorbed antimicrobial such as clindamycin or a first-generation cephalosporin, provided the clinical response is good and C-reactive protein normalizes within 7 to 10 days.	Clindamycin	168-179	C-reactive protein	Homo sapiens	260-278
22301615-8	2012	NAP2 isolates were homogeneous (85.5% had SmaI PFGE pattern 0003) and demonstrated low susceptibility to moxifloxacin (6.6%) and clindamycin (1.6%) compared with non-NAP2 isolates (64.1-93.2% moxifloxacin susceptible; 14.1-28.2% clindamycin susceptible).	Clindamycin	129-140	napsin B aspartic peptidase, pseudogene	Homo sapiens	0-4
22301615-8	2012	NAP2 isolates were homogeneous (85.5% had SmaI PFGE pattern 0003) and demonstrated low susceptibility to moxifloxacin (6.6%) and clindamycin (1.6%) compared with non-NAP2 isolates (64.1-93.2% moxifloxacin susceptible; 14.1-28.2% clindamycin susceptible).	Clindamycin	229-240	napsin B aspartic peptidase, pseudogene	Homo sapiens	0-4
21976769-9	2011	The rates of resistance (including intermediate) for hVISA were as follows: oxacillin, 82%; erythromycin, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%.	Clindamycin	111-122	mitochondrial antiviral signaling protein	Homo sapiens	53-58
21417600-4	2011	Thus, the new patent pending TRI-726 drug delivery matrix was both inert and non-reactive toward the incorporated clindamycin in terms of chemical degradation (< 10% degradation under accelerated conditions over 6 months) and antimicrobial activity.	Clindamycin	114-125	tRNA-Ile (anticodon AAT) 9-1	Homo sapiens	29-32
20370748-9	2010	For outpatient cellulitis, PEPs selected clindamycin (30.6%), trimethoprim-sulfa (27.0%), and first-generation cephalosporins (22.7%); methicillin-sensitive S. aureus (MSSA) was routinely covered, but many regimens failed to cover CA-MRSA (32.5%) or group A streptococcus (27.0%).	Clindamycin	41-52	leucine aminopeptidase 3	Homo sapiens	27-31
20939914-0	2010	Protective effect of rifampicin and clindamycin impregnated devices against Staphylococcus spp.	Clindamycin	36-47	histocompatibility minor 13	Homo sapiens	91-94
20305014-9	2010	Antibiotics that decrease toxin production, such as clindamycin, may provide benefit, and their efficacy against bacterial superinfections in children with varicella should be studied.	Clindamycin	52-63	AT695_RS01930	Staphylococcus aureus	26-31
20370748-11	2010	PEPs elected to prescribe trimethoprim-sulfamethoxazole (TMP-Sx; 50.0%) or clindamycin (32.7%) after drainage; only 5% selected CA-MRSA-inactive agents.	Clindamycin	75-86	leucine aminopeptidase 3	Homo sapiens	0-4
18623043-1	2008	Clindamycin is an antimicrobial agent metabolized by CYP3A4.	Clindamycin	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-59
19647824-0	2009	Effect of clindamycin treatment on vaginal inflammatory markers in pregnant women with bacterial vaginosis and a positive fetal fibronectin test.	Clindamycin	10-21	fibronectin 1	Homo sapiens	128-139
19489364-8	2009	Our CA-MRSA isolates were 98.6% sensitive to trimethoprim-sulfamethoxasole, 94.4% sensitive to tetracycline, 90.8% sensitive to clindamycin, and 59.9% sensitive to levofloxacin.	Clindamycin	128-139	solute carrier family 9 member A6	Homo sapiens	7-11
18505790-6	2008	CYP3A4 activity was significantly increased by rifampin (9.7-fold), nafcillin and dicloxacillin (5.9-fold), and weakly induced (2-fold) by tetracycline, sufisoxazole, troleandomycin, and clindamycin.	Clindamycin	187-198	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
18544597-0	2008	Susceptibility of 170 isolates of the USA300 clone of MRSA to macrolides, clindamycin and the novel ketolide cethromycin.	Clindamycin	74-85	solute carrier family 9 member A6	Homo sapiens	54-58
18505790-9	2008	In summary, nafcillin, dicloxacillin, cephradine, tetracycline, sulfixoxazole, erythromycin, clindamycin, and griseofulvin exhibit a clear propensity to induce CYP3A4 and warrant further clinical investigation.	Clindamycin	93-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	160-166
18592743-13	2008	A majority of enterotoxin-producing isolates were resistant to 2 of 10 antibiotics tested, ceftriaxone and clindamycin.	Clindamycin	107-118	cpe	Clostridium perfringens	14-25
18077631-0	2008	Differences in potential for selection of clindamycin-resistant mutants between inducible erm(A) and erm(C) Staphylococcus aureus genes.	Clindamycin	42-53	rRNA methylase Erm(A)	Staphylococcus aureus	90-96
18234877-9	2008	Clindamycin resistance remained low until 2003-2004, when 26.7% of strains were resistant; this was associated with the emergence of multidrug-resistant type 19A strains.	Clindamycin	0-11	SLAM family member 7	Homo sapiens	158-161
18077631-6	2008	The frequencies of mutation to clindamycin resistance for the erm(A) isolates (mean +/- standard deviation, 3.4 x 10(-8) +/- 2.4 x 10(-8)) were only slightly higher than those for the controls (1.1 x 10(-8) +/- 6.4 x 10(-9)).	Clindamycin	31-42	rRNA methylase Erm(A)	Staphylococcus aureus	62-68
18077631-7	2008	By contrast, erm(C) isolates displayed a mean frequency of mutation to clindamycin resistance (4.7 x 10(-7) +/- 5.5 x 10(-7)) 14-fold higher than that of the S. aureus isolates with erm(A).	Clindamycin	71-82	rRNA methylase Erm(A)	Staphylococcus aureus	182-188
18077631-9	2008	We conclude that erm(C) and erm(A) have different genetic potentials for selection of clindamycin-resistant mutants.	Clindamycin	86-97	rRNA methylase Erm(A)	Staphylococcus aureus	28-34
17083011-6	2006	Three techniques were used to study antibiotic (penicillin V, erythromycin, azithromycin, cephalothin, and clindamycin) killing of ingested GAS: examination by electron microscopy of ultrathin sections of ingested GAS, qualitative determination of intra-epithelial cell antibiotic, and special stain evaluation of intracellular GAS viability after epithelial cell exposure to antibiotics.	Clindamycin	107-118	gastrin	Homo sapiens	140-143
19011777-2	2008	An increase in acetylcholine concentration caused by neostigmine and calcium may enhance the use-dependent ion channel block of the nicotinic acetylcholine receptor caused by clindamycin.	Clindamycin	175-186	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	132-164
18250924-6	2007	An exception is the oral treatment of multidrug-resistant serotype 19A strains in children in the USA, as these are resistant to amoxicillin, oral cephalosporins, macrolides, clindamycin and co-trimoxazole.	Clindamycin	175-186	SLAM family member 7	Homo sapiens	67-70
17445081-1	2007	OBJECTIVE: To determine the clinical efficacy of subconjunctival injection of clindamycin in the treatment of naturally occurring infectious bovine keratoconjunctivitis (IBK).	Clindamycin	78-89	IBK	Bos taurus	170-173
17288904-11	2007	The msrA gene was present in all isolates with the MSB phenotype, and the ermC gene was the most common among clindamycin-resistant strains with the MLSB phenotype (constitutive or inducible).	Clindamycin	110-121	ErmC	Staphylococcus aureus	74-78
17083011-10	2006	Cephalothin, a cephalosporin, and clindamycin were more effective in killing ingested GAS than was penicillin, but they were less effective than erythromycin or azithromycin.	Clindamycin	34-45	gastrin	Homo sapiens	86-89
16940078-2	2006	Proton pump inhibitor treatment of clindamycin-treated mice elevated the gastric pH and facilitated the establishment of colonization of the large intestine by vancomycin-resistant Enterococcus spp.	Clindamycin	35-46	ATPase, H+/K+ exchanging, gastric, alpha polypeptide	Mus musculus	0-11
16439092-0	2006	Rapid determination of clindamycin in medicine with myoglobin-luminol chemiluminescence system.	Clindamycin	23-34	myoglobin	Homo sapiens	52-61
16617002-1	2006	A simple high-performance liquid-electrospray ionization tandem mass spectrometric (HPLC-ESI-MSn) method has been developed for the rapid identification of clindamycin and its related minor impurities in bulk drug.	Clindamycin	156-167	moesin	Homo sapiens	93-96
16617002-4	2006	According to the fragmentation mechanism of mass spectrometry and HPLC-UV-ESI-MSn data, six impurities of clindamycin have been identified on-line.	Clindamycin	106-117	moesin	Homo sapiens	78-81
16439092-1	2006	A sensitive chemiluminescence method, based on the inhibitory effect of clindamycin on the chemiluminescence reaction between luminol and myoglobin in a flow-injection system, is proposed for the determination of clindamycin.	Clindamycin	72-83	myoglobin	Homo sapiens	138-147
16439092-1	2006	A sensitive chemiluminescence method, based on the inhibitory effect of clindamycin on the chemiluminescence reaction between luminol and myoglobin in a flow-injection system, is proposed for the determination of clindamycin.	Clindamycin	213-224	myoglobin	Homo sapiens	138-147
16490583-0	2006	Oral clindamycin 300 mg BID compared with oral amoxicillin/clavulanic acid 1 g BID in the outpatient treatment of acute recurrent pharyngotonsillitis caused by group a beta-hemolytic streptococci: an international, multicenter, randomized, investigator-blinded, prospective trial in patients between the ages of 12 and 60 years.	Clindamycin	5-16	BH3 interacting domain death agonist	Homo sapiens	24-27
16490583-22	2006	CONCLUSIONS: In this study in patients with acute recurrent GABHS pharyngotonsillitis, oral clindamycin 300 mg BID and oral amoxicillin/clavulanic acid 1 g BID achieved comparable rates of bacteriologic eradication at 12 days and 3 months and comparable clinical cure rates at 3 months.	Clindamycin	92-103	BH3 interacting domain death agonist	Homo sapiens	111-114
16341337-5	2005	Compared with those reported from the US and other countries, CA-MRSA isolates in Taiwan did not always harbor type IV staphylococcal cassette chromosome (SCCmec) and were resistant to multiple non-beta-lactam antibiotics, including clindamycin and macrolides.	Clindamycin	233-244	solute carrier family 9 member A6	Homo sapiens	65-69
16771232-2	2006	Clindamycin was separated from the internal standard (phenobarbital) on a Luna C18 column (250 x 4.6 mm, 5 mm particle size: Phenomenex, USA), with retention times of 5.6 and 14.2 minutes, respectively.	Clindamycin	0-11	Bardet-Biedl syndrome 9	Homo sapiens	79-82
16091044-1	2005	The gene product of cfr from Staphylococcus sciuri confers resistance to chloramphenicol, florfenicol and clindamycin in Staphylococcus spp.	Clindamycin	106-117	florfenicol/chloramphenicol resistance protein	Staphylococcus sciuri	20-23
16091044-5	2005	As chloramphenicol/florfenicol and clindamycin have partly overlapping drug binding sites on the ribosome, the most likely explanation is that Cfr modifies the RNA in the drug binding site.	Clindamycin	35-46	florfenicol/chloramphenicol resistance protein	Escherichia coli	143-146
16091044-9	2005	The results show that Cfr is an RNA methyltransferase that targets nucleotide A2503 and inhibits ribose methylation at nucleotide C2498, thereby causing resistance to chloramphenicol, florfenicol and clindamycin.	Clindamycin	200-211	florfenicol/chloramphenicol resistance protein	Escherichia coli	22-25
15795123-9	2005	RESULTS: Nadifloxacin as well as macrolide antibiotics and clindamycin inhibited IL-12 and IFN-gamma production by PBMC stimulated by heat-killed P. acnes.	Clindamycin	59-70	interferon gamma	Homo sapiens	91-100
15182732-9	2004	Clindamycin application led to a dose-dependent significant suppression of the fMLP-induced oxidative response in patients with sepsis and MODS, but not in healthy donors or septic patients in the absence of MODS.	Clindamycin	0-11	formyl peptide receptor 1	Homo sapiens	79-83
15635047-4	2005	We found that GBS exposed to rifampin or clindamycin (versus beta-lactam antibiotics) stimulated less TNF secretion and inducible nitric oxide synthase (iNOS) protein accumulation in RAW 264.7 cells.	Clindamycin	41-52	tumor necrosis factor	Mus musculus	102-105
15635047-4	2005	We found that GBS exposed to rifampin or clindamycin (versus beta-lactam antibiotics) stimulated less TNF secretion and inducible nitric oxide synthase (iNOS) protein accumulation in RAW 264.7 cells.	Clindamycin	41-52	nitric oxide synthase 2, inducible	Mus musculus	120-151
15635047-4	2005	We found that GBS exposed to rifampin or clindamycin (versus beta-lactam antibiotics) stimulated less TNF secretion and inducible nitric oxide synthase (iNOS) protein accumulation in RAW 264.7 cells.	Clindamycin	41-52	nitric oxide synthase 2, inducible	Mus musculus	153-157
15095923-1	2003	The aim of this study was to compare the influence of antimicrobials (clindamycin, metronidazole and polymyxin B) on the expression of adhesion molecules (VCAM-1, ICAM-1 and E-selectin) on the HMEC-1 cell line stimulated by LPS and enterotoxin of B. fragilis.	Clindamycin	70-81	vascular cell adhesion molecule 1	Homo sapiens	155-161
12814964-2	2003	In this report, evidence is presented that the S-oxidation of clindamycin is primarily mediated by CYP3A.	Clindamycin	62-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-104
12814964-9	2003	Of the P450 enzymes examined, only the activity of CYP3A4 was inhibited (approximately 26%) by coincubation with clindamycin (100 microM).	Clindamycin	113-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
12814964-10	2003	Thus, it is concluded that CYP3A4 appears to account for the largest proportion of the observed P450 catalytic clindamycin S-oxidase activity in vitro, and this activity may be extrapolated to the in vivo condition.	Clindamycin	111-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
15095923-1	2003	The aim of this study was to compare the influence of antimicrobials (clindamycin, metronidazole and polymyxin B) on the expression of adhesion molecules (VCAM-1, ICAM-1 and E-selectin) on the HMEC-1 cell line stimulated by LPS and enterotoxin of B. fragilis.	Clindamycin	70-81	intercellular adhesion molecule 1	Homo sapiens	163-169
15095923-1	2003	The aim of this study was to compare the influence of antimicrobials (clindamycin, metronidazole and polymyxin B) on the expression of adhesion molecules (VCAM-1, ICAM-1 and E-selectin) on the HMEC-1 cell line stimulated by LPS and enterotoxin of B. fragilis.	Clindamycin	70-81	selectin E	Homo sapiens	174-184
15095923-6	2003	Clindamycin, metronidazole and polymyxin B supressed the ICAM-1 expression when endothelium was stimulated with B. fragilis LPS and augmented ICAM-1 expression by Tox 1 and Tox 2.	Clindamycin	0-11	intercellular adhesion molecule 1	Homo sapiens	57-63
15095923-6	2003	Clindamycin, metronidazole and polymyxin B supressed the ICAM-1 expression when endothelium was stimulated with B. fragilis LPS and augmented ICAM-1 expression by Tox 1 and Tox 2.	Clindamycin	0-11	intercellular adhesion molecule 1	Homo sapiens	142-148
11292717-3	2001	The effect was abolished by a gene conferring resistance to macrolides-lincosamides-streptogramin B, showing that differential inhibition of protein synthesis is responsible; remarkably, however, subinhibitory clindamycin blocked production of several of the individual exoprotein genes, including spa (encoding protein A), hla (encoding alpha-hemolysin), and spr (encoding serine protease), at the level of transcription, suggesting that the primary effect must be differential inhibition of the synthesis of one or more regulatory proteins.	Clindamycin	210-221	AT695_RS10460	Staphylococcus aureus	374-389
12019067-6	2002	ErmN monomethylation predictably confers high resistance to the lincosamides clindamycin and lincomycin, intermediate resistance to the macrolides clarithromycin and erythromycin, and low resistance to the streptogramin B pristinamycin IA.	Clindamycin	77-88	ermin	Homo sapiens	0-4
11502543-4	2001	Pretreatment with CLI significantly improved survival in a dose-dependent manner (CLI, at 160, 300, and 440 mg/kg) and significantly lowered the peak concentrations of tumor necrosis factor alpha and interleukin-1beta (IL-1beta) in serum.	Clindamycin	18-21	tumor necrosis factor	Mus musculus	168-195
11502543-4	2001	Pretreatment with CLI significantly improved survival in a dose-dependent manner (CLI, at 160, 300, and 440 mg/kg) and significantly lowered the peak concentrations of tumor necrosis factor alpha and interleukin-1beta (IL-1beta) in serum.	Clindamycin	18-21	interleukin 1 beta	Mus musculus	200-217
11502543-4	2001	Pretreatment with CLI significantly improved survival in a dose-dependent manner (CLI, at 160, 300, and 440 mg/kg) and significantly lowered the peak concentrations of tumor necrosis factor alpha and interleukin-1beta (IL-1beta) in serum.	Clindamycin	18-21	interleukin 1 beta	Mus musculus	219-227
11144420-5	2000	The overall frequency of drug resistance traits among the 1,749 MRSA strains was high (over 70% and up to and over 90% of the strains) to ciprofloxacin, erythromycin, clindamycin, gentamicin, and tetracycline, and was somewhat less frequent to sulfamethoxazole-trimethoprim (45%), chloramphenicol (30%), and rifampin (38%).	Clindamycin	167-178	solute carrier family 9 member A6	Homo sapiens	64-68
11760173-3	2001	All 3 children responded to antibiotic regimens consisting of cefotaxime for 10 d, ceftriaxone for 3 weeks and ceftriaxone plus clindamycin for 4 weeks, respectively.	Clindamycin	128-139	paired box 5	Homo sapiens	0-5
10348770-2	1999	Here it is shown that the Escherichia coli msbB mutant, which elaborates defective, penta-acylated lipid A, is practically as resistant to a representative set of hydrophobic solutes (rifampin, fusidic acid, erythromycin, clindamycin, and azithromycin) as the parent-type control strain.	Clindamycin	222-233	lipid A biosynthesis (KDO)2-(lauroyl)-lipid IVA acyltransferase	Escherichia coli	43-47
10049276-6	1999	Pretreatment of E. coli with CLDM for 4 or 18 h before the addition of CAZ significantly suppressed the concentrations of endotoxin, TNF-alpha, and IL-1 beta in a time-dependent manner.	Clindamycin	29-33	tumor necrosis factor	Homo sapiens	133-142
10049276-6	1999	Pretreatment of E. coli with CLDM for 4 or 18 h before the addition of CAZ significantly suppressed the concentrations of endotoxin, TNF-alpha, and IL-1 beta in a time-dependent manner.	Clindamycin	29-33	interleukin 1 beta	Homo sapiens	148-157
8723488-3	1996	In vitro exposure to clindamycin, piritrexim, and pyrimethamine caused an inhibition of human T lymphocyte proliferation in response to mitogen, antigen, and interleukin-2 stimulation.	Clindamycin	21-32	interleukin 2	Homo sapiens	158-171
9789363-10	1998	MRSA-strains were more resistant to imipenem, ofloxacin, gentamicin, trimethoprim-sulfamethoxazole, tetracycline, erythromycin and clindamycin as oxacillin-sensitive Straphylococcus aureus strains.	Clindamycin	131-142	solute carrier family 9 member A6	Homo sapiens	0-4
9055997-8	1997	The tumor necrosis factor alpha levels in the untreated animals were high compared to those for rats treated with trovafloxacin or clindamycin plus gentamicin.	Clindamycin	131-142	tumor necrosis factor	Rattus norvegicus	4-31
9011117-0	1996	Effect of recombinant human granulocyte colony-stimulating factor on combination therapy with aztreonam and clindamycin for infections in neutropenic patients with hematologic diseases.	Clindamycin	108-119	colony stimulating factor 3	Homo sapiens	28-65
9011117-1	1996	The present multicenter study was performed to evaluate the effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) on combination therapy using aztreonam (AZT) and clindamycin (CLDM) to treat severe infection in neutropenic patients with hematologic diseases.	Clindamycin	185-196	colony stimulating factor 3	Homo sapiens	88-125
9011117-1	1996	The present multicenter study was performed to evaluate the effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) on combination therapy using aztreonam (AZT) and clindamycin (CLDM) to treat severe infection in neutropenic patients with hematologic diseases.	Clindamycin	198-202	colony stimulating factor 3	Homo sapiens	88-125
8559623-3	1995	Using 1994 National Committee for Clinical Laboratory Standards breakpoints for pneumococci (unavailable for oral cephalosporins except cefuroxime), highly PRSP strains were almost uniformly susceptible to clindamycin and vancomycin.	Clindamycin	206-217	HtrA serine peptidase 3	Homo sapiens	156-160
8492751-9	1993	The overall rate of success with modifications (Amphotericin B, Vancomycin, Clindamycin, Metronidazole) was higher in Reg.	Clindamycin	76-87	regenerating family member 1 alpha	Homo sapiens	118-121
7492105-0	1995	In vitro and in vivo effects of penicillin and clindamycin on expression of group A beta-hemolytic streptococcal capsule.	Clindamycin	47-58	amyloid beta precursor protein	Homo sapiens	82-88
7920440-0	1994	Inhibitory effect of clindamycin on production of beta-lactamase in beta-lactam-resistant bacteria.	Clindamycin	21-32	Beta lactamase	Pseudomonas aeruginosa	50-64
7920440-1	1994	The inhibitory effect of clindamycin on beta-lactamase biosynthesis was investigated in beta-lactam resistant bacteria with inducible and/or constitutive production of the enzyme(s).	Clindamycin	25-36	Beta lactamase	Pseudomonas aeruginosa	40-54
7920440-4	1994	Although clindamycin had no appreciable effect on bacteria growth at concentrations up to 50 micrograms/ml, it suppressed inducible beta-lactamase biosynthesis almost completely at a concentration of 20 micrograms/ml.	Clindamycin	9-20	Beta lactamase	Pseudomonas aeruginosa	132-146
7920440-6	1994	Thus, it was estimated that a high concentration of clindamycin was required to suppress beta-lactamase biosynthesis in beta-lactamase producing bacteria of the constitutive type.	Clindamycin	52-63	Beta lactamase	Pseudomonas aeruginosa	89-103
7920440-6	1994	Thus, it was estimated that a high concentration of clindamycin was required to suppress beta-lactamase biosynthesis in beta-lactamase producing bacteria of the constitutive type.	Clindamycin	52-63	Beta lactamase	Pseudomonas aeruginosa	120-134
1507452-8	1992	As for drug susceptibility, MRSA strains with coagulase type VII were more sensitive to clindamycin and more resistant to minocyclin compared to MRSA with other coagulase types.	Clindamycin	88-99	solute carrier family 9 member A6	Homo sapiens	28-32
2380767-0	1990	Clindamycin in the treatment of an outbreak of streptococcal pharyngitis in a kibbutz due to beta-lactamase producing organisms.	Clindamycin	0-11	beta-lactamase	Staphylococcus aureus	93-107
1294622-6	1992	Among the lincosamides, clindamycine notably stimulated the release of TNF and IL-6, while lincomycine induced a notable increment of IL-4 from monocytes.	Clindamycin	24-36	tumor necrosis factor	Homo sapiens	71-74
1294622-6	1992	Among the lincosamides, clindamycine notably stimulated the release of TNF and IL-6, while lincomycine induced a notable increment of IL-4 from monocytes.	Clindamycin	24-36	interleukin 6	Homo sapiens	79-83
34946181-8	2021	Most of clindamycin-resistant GBS strains (76%) were serotype III-ST17 and possessed the genetic markers of the emerging multidrug resistant (MDR) CC-17 sub-clone.	Clindamycin	8-19	cell adhesion molecule 1	Homo sapiens	66-70
2163244-7	1990	Clindamycin, which enters phagocytes by the cell membrane adenosine (nucleoside) transport system, had only a modest effect on FMLP-mediated superoxide production but inhibited the microbial particle-induced response by approximately 50%.	Clindamycin	0-11	formyl peptide receptor 1	Homo sapiens	127-131
34454095-0	2021	Targeting antibiotic tolerance in anaerobic biofilms associated with oral diseases: Human antimicrobial peptides LL-37 and lactoferricin enhance the antibiotic efficacy of amoxicillin, clindamycin and metronidazole.	Clindamycin	185-196	cathelicidin antimicrobial peptide	Homo sapiens	113-118
34718190-0	2021	Distribution of erm genes among MRSA isolates with resistance to clindamycin in a Chinese teaching hospital.	Clindamycin	65-76	solute carrier family 9 member A6	Homo sapiens	32-36
34718190-1	2021	The objective of this study was to analyze erythromycin and clindamycin resistance patterns among different MRSA lineages in China.	Clindamycin	60-71	solute carrier family 9 member A6	Homo sapiens	108-112
34718190-4	2021	Additionally, 88.2% (60/68) of the ST59 MRSA isolates and 78.9% (15/19) of the ST239 MRSA isolates had constitutive resistance to clindamycin, while 82.0% (123/150) of the ST5 MRSA isolates showed inducible clindamycin resistance.	Clindamycin	130-141	solute carrier family 9 member A6	Homo sapiens	40-44
34718190-4	2021	Additionally, 88.2% (60/68) of the ST59 MRSA isolates and 78.9% (15/19) of the ST239 MRSA isolates had constitutive resistance to clindamycin, while 82.0% (123/150) of the ST5 MRSA isolates showed inducible clindamycin resistance.	Clindamycin	130-141	solute carrier family 9 member A6	Homo sapiens	85-89
34718190-4	2021	Additionally, 88.2% (60/68) of the ST59 MRSA isolates and 78.9% (15/19) of the ST239 MRSA isolates had constitutive resistance to clindamycin, while 82.0% (123/150) of the ST5 MRSA isolates showed inducible clindamycin resistance.	Clindamycin	207-218	solute carrier family 9 member A6	Homo sapiens	176-180
34718190-8	2021	Summarily, high erythromycin and clindamycin resistance rates were observed in MRSA isolates.	Clindamycin	33-44	solute carrier family 9 member A6	Homo sapiens	79-83
34718190-11	2021	Erythromycin and clindamycin resistance genes transfer between MRSA isolates in healthcare settings remains a problem, and infection control procedures should be applied.	Clindamycin	17-28	solute carrier family 9 member A6	Homo sapiens	63-67
34511281-0	2021	Cement Loaded With High-Dose Gentamicin and Clindamycin Reduces the Risk of Subsequent Infection After One-Stage Hip or Knee Arthroplasty Exchange for Periprosthetic Infection: A Preliminary Study.	Clindamycin	44-55	hedgehog interacting protein	Homo sapiens	113-116
34689824-11	2021	Blood cultures and sensitivity showed group A beta-hemolytic streptococci sensitive to penicillin G and clindamycin.	Clindamycin	104-115	amyloid beta precursor protein	Homo sapiens	44-50
34656079-4	2021	ErmX was present in the genome sequence and this isolate owned the resistance to erythromycin and clindamycin.	Clindamycin	98-109	Erm(X)	Corynebacterium diphtheriae	0-4
34454095-0	2021	Targeting antibiotic tolerance in anaerobic biofilms associated with oral diseases: Human antimicrobial peptides LL-37 and lactoferricin enhance the antibiotic efficacy of amoxicillin, clindamycin and metronidazole.	Clindamycin	185-196	lactotransferrin	Homo sapiens	123-136
34454095-4	2021	LL-37 and Lactoferricin enhanced the anti-biofilm effect of amoxicillin and clindamycin in facultative anaerobic biofilms.	Clindamycin	76-87	cathelicidin antimicrobial peptide	Homo sapiens	0-5
34454095-4	2021	LL-37 and Lactoferricin enhanced the anti-biofilm effect of amoxicillin and clindamycin in facultative anaerobic biofilms.	Clindamycin	76-87	lactotransferrin	Homo sapiens	10-23
34454095-7	2021	However, when combined with LL-37 or Lactoferricin, the reduction of obligate anaerobic biofilms was markedly enhanced for all antibiotics, even for amoxicillin and clindamycin.	Clindamycin	165-176	cathelicidin antimicrobial peptide	Homo sapiens	28-33
34454095-7	2021	However, when combined with LL-37 or Lactoferricin, the reduction of obligate anaerobic biofilms was markedly enhanced for all antibiotics, even for amoxicillin and clindamycin.	Clindamycin	165-176	lactotransferrin	Homo sapiens	37-50
35545893-3	2022	The aim was to study the ability of native and iron-saturated lactoferrin to reverse the effects of clindamycin on gut microbiota and intestinal Toll-like receptor (TLR) expression in a murine model.	Clindamycin	100-111	lactotransferrin	Mus musculus	62-73
35545893-3	2022	The aim was to study the ability of native and iron-saturated lactoferrin to reverse the effects of clindamycin on gut microbiota and intestinal Toll-like receptor (TLR) expression in a murine model.	Clindamycin	100-111	toll-like receptor 1	Mus musculus	165-168
35545893-13	2022	Conclusion: In a situation of intestinal dysbiosis induced by clindamycin, lactoferrin restores the normal levels of some anti-inflammatory bacteria and TLRs and, therefore, could be a good ingredient to be added to functional foods.	Clindamycin	62-73	lactotransferrin	Mus musculus	75-86
35625345-6	2022	As clindamycin is metabolized by the CYP3A4/5 enzymes to bioactive N-demethyl and sulfoxide metabolites, knowledge of the potential relevance of the drug"s metabolites and disposition in special populations is of interest.	Clindamycin	3-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-45
35273901-8	2022	Molecular docking results revealed that clindamycin has a higher affinity towards the catalytic sides of DPP-4 and built solid hydrophobic and polar interactions with the amino acids involved in the binding region of DPP-4, such as S1 subsite, S2 subsite and S2 extensive subsite.	Clindamycin	40-51	dipeptidyl peptidase 4	Homo sapiens	105-110
35273901-8	2022	Molecular docking results revealed that clindamycin has a higher affinity towards the catalytic sides of DPP-4 and built solid hydrophobic and polar interactions with the amino acids involved in the binding region of DPP-4, such as S1 subsite, S2 subsite and S2 extensive subsite.	Clindamycin	40-51	dipeptidyl peptidase 4	Homo sapiens	217-222
35273901-9	2022	MD simulations results showed clindamycin as potent virtual hit and suggested that it binds with DPP-4 in competitive manner, which virtually indicate that besides antibiotic activity clindamycin has anti-diabetic activity.	Clindamycin	30-41	dipeptidyl peptidase 4	Homo sapiens	97-102
35273901-9	2022	MD simulations results showed clindamycin as potent virtual hit and suggested that it binds with DPP-4 in competitive manner, which virtually indicate that besides antibiotic activity clindamycin has anti-diabetic activity.	Clindamycin	184-195	dipeptidyl peptidase 4	Homo sapiens	97-102
35476856-8	2022	Treatment of the osteoblasts with 150 mug/mL clindamycin for 1 minute significantly increased the expression of ALP (P = .002).	Clindamycin	45-56	alkaline phosphatase, placental	Homo sapiens	112-115
35044221-14	2022	Subinhibitory concentrations (sub-MIC) of antibiotics modulate in vitro toxins expression in S. aureus: clindamycin (CLI) and linezolid (LIN) display an anti-toxin effect on Panton-Valentine leucocidin and alpha-hemolysin production, while oxacillin (OXA) has an inducing effect.	Clindamycin	104-115	AT695_RS11870	Staphylococcus aureus	206-221
35044221-14	2022	Subinhibitory concentrations (sub-MIC) of antibiotics modulate in vitro toxins expression in S. aureus: clindamycin (CLI) and linezolid (LIN) display an anti-toxin effect on Panton-Valentine leucocidin and alpha-hemolysin production, while oxacillin (OXA) has an inducing effect.	Clindamycin	117-120	AT695_RS11870	Staphylococcus aureus	206-221
35159037-0	2022	Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide.	Clindamycin	89-100	mechanistic target of rapamycin kinase	Homo sapiens	125-129
2500139-9	1989	These data illustrate the efficacy of clindamycin therapy in eradicating group A beta-hemolytic streptococci, as well as BLPB, in recurrent inflamed tonsils, especially in persons aged 12 years old and younger.	Clindamycin	38-49	amyloid beta precursor protein	Homo sapiens	79-85
35055155-2	2022	Clindamycin (CLIN) or metronidazole (MET) was added to a polymer solution and electrospun into fibrous mats, which were processed via cryomilling to obtain CLIN- or MET-laden fibrous microparticles.	Clindamycin	0-11	SAFB like transcription modulator	Homo sapiens	165-168
35055155-2	2022	Clindamycin (CLIN) or metronidazole (MET) was added to a polymer solution and electrospun into fibrous mats, which were processed via cryomilling to obtain CLIN- or MET-laden fibrous microparticles.	Clindamycin	13-17	SAFB like transcription modulator	Homo sapiens	165-168
2575870-4	1989	TNF and neopterin levels were markedly increased in the plasma of patients and remained slightly elevated after chemotherapy with clindamycin.	Clindamycin	130-141	tumor necrosis factor	Homo sapiens	0-3
2767221-6	1989	Strain CT28 was resistant to josamycin, erythromycin, roxithromycin, lincomycin and clindamycin but sensitive to minocycline.	Clindamycin	84-95	leucine zipper protein 4	Homo sapiens	7-11
3169291-2	1988	We conclude that it is appropriate in women with this stage of PID to treat initially with clindamycin and an aminoglycoside.	Clindamycin	91-102	metastasis associated 1 family member 2	Homo sapiens	63-66
2527734-2	1989	Incubation with clindamycin caused an increase in the proportion of granulocytes bearing receptors for the Fc portion of IgG (Fc gamma-R) and C3b (C3b-R).	Clindamycin	16-27	endogenous retrovirus group K member 3	Homo sapiens	142-145
2527734-2	1989	Incubation with clindamycin caused an increase in the proportion of granulocytes bearing receptors for the Fc portion of IgG (Fc gamma-R) and C3b (C3b-R).	Clindamycin	16-27	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	147-152
3144525-0	1988	In-vitro and in-vivo bacterocodal interactions of clindamycin and ceftazidime, by non-beta-lactamase mechanisms, in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive beta-lactamase overproducing strain.	Clindamycin	50-61	Beta lactamase	Pseudomonas aeruginosa	86-100
3144525-0	1988	In-vitro and in-vivo bacterocodal interactions of clindamycin and ceftazidime, by non-beta-lactamase mechanisms, in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive beta-lactamase overproducing strain.	Clindamycin	50-61	Beta lactamase	Pseudomonas aeruginosa	190-204
3144525-6	1988	In vitro, clindamycin prevented spontaneous mutation of PA-96 to the stably-derepressed state for beta-lactamase overproduction and also enhanced reversion of derepressed cells of PA-48 to the ceftazidime-susceptible parental phenotype by approximately 2 log10 cfu/ml.	Clindamycin	10-21	Beta lactamase	Pseudomonas aeruginosa	98-112
3492375-2	1986	The most pronounced effects were seen after administration of bacitracin, clindamycin or vancomycin: the electrophoretic mucin pattern in faeces changed from a normal conventional pattern to a specific pattern similar to that found in germ-free rats.	Clindamycin	74-85	solute carrier family 13 member 2	Rattus norvegicus	121-126
3137275-7	1988	Like erythromycin and rifampin, clindamycin, which is highly concentrated in human alveolar macrophages, was capable of inhibiting the intracellular multiplication of L. pneumophila but failed to kill the bacteria in nonactivated or IFN-gamma-activated monocytes.	Clindamycin	32-43	interferon gamma	Homo sapiens	233-242
3020254-1	1986	The effect of clindamycin on Fc receptor expression has been investigated with mouse peritoneal macrophages and human peripheral blood monocytes.	Clindamycin	14-25	Fc receptor	Mus musculus	29-40
6315672-0	1983	Influence of clindamycin on fibronectin-staphylococcal interactions.	Clindamycin	13-24	fibronectin 1	Homo sapiens	28-39
6315672-1	1983	This report examines the effects of subinhibitory concentrations of of clindamycin on fibronectin-staphylococcal interactions.	Clindamycin	71-82	fibronectin 1	Homo sapiens	86-97
6315672-2	1983	Using in-vitro binding assays, exposure of staphylococci to subinhibitory concentrations of clindamycin results in a dose-dependent decrease in fibronectin"s ability to bind to treated organisms.	Clindamycin	92-103	fibronectin 1	Homo sapiens	144-155
6315672-4	1983	Serum-mediated phagocytosis of clindamycin-treated organisms remained effective despite the reduction in fibronectin binding capabilities.	Clindamycin	31-42	fibronectin 1	Homo sapiens	105-116
6315672-5	1983	These results suggest that the clinical use of clindamycin has the potential to affect bacterial binding of fibronectin, thus modifying the adherence of organisms to host surfaces without adversely effecting their clearance by the reticuloendothelial system.	Clindamycin	47-58	fibronectin 1	Homo sapiens	108-119
7096266-1	1982	Bacteroides fragilis TMP10, which is clindamycin-erythromycin resistant (Clnr) and tetracycline resistant (Tetr), contains several plasmids and is capable of transferring drug resistance markers to suitable recipients.	Clindamycin	37-48	oligodendrocytic myelin paranodal and inner loop protein	Homo sapiens	21-26
6414365-11	1983	These in vitro effects of clindamycin on strain 55 that were related to prevention of derepression of beta-lactamase were confirmed in vivo with an animal model of infection.	Clindamycin	26-37	Beta lactamase	Pseudomonas aeruginosa	102-116
7096266-7	1982	A complex interaction between the autonomous plasmid pBFTM10 and a tetracycline transfer element also present in strain TMP10 was observed since pretreatment of this donor with tetracycline or clindamycin resulted in a marked increase in transfer of both tetracycline and clindamycin resistance.	Clindamycin	193-204	oligodendrocytic myelin paranodal and inner loop protein	Homo sapiens	120-125
7096266-7	1982	A complex interaction between the autonomous plasmid pBFTM10 and a tetracycline transfer element also present in strain TMP10 was observed since pretreatment of this donor with tetracycline or clindamycin resulted in a marked increase in transfer of both tetracycline and clindamycin resistance.	Clindamycin	272-283	oligodendrocytic myelin paranodal and inner loop protein	Homo sapiens	120-125
7014632-4	1981	An M-protein positive strain of S. pyogenes was grown in varying concentrations of clindamycin at levels lower than those which inhibited growth, i.e., at levels less than the minimal inhibitory concentration.	Clindamycin	83-94	myomesin 2	Homo sapiens	3-12
7014632-9	1981	Streptococci exposed to clindamycin during growth were largely denuded of surface "fuzz," the hairlike structures bearing M-protein.	Clindamycin	24-35	myomesin 2	Homo sapiens	122-131
438530-1	1979	A clindamycin- and erythromycin-resistant strain of Bacteroides fragilis, TMP10, that had been isolated from a blood culture transferred its drug resistance in a Millipore mating procedure to another strain of B. fragilis, TM2000, and to a strain of Bacteroides thetaiotaomicron.	Clindamycin	2-13	oligodendrocytic myelin paranodal and inner loop protein	Homo sapiens	74-79
7265601-7	1980	These results suggest that chloramphenicol and clindamycin may inhibit Ca2+ influx through the Ca2+ channels across the smooth muscle cell membrane.	Clindamycin	47-58	LOW QUALITY PROTEIN: carbonic anhydrase 2	Cavia porcellus	71-74
7265601-7	1980	These results suggest that chloramphenicol and clindamycin may inhibit Ca2+ influx through the Ca2+ channels across the smooth muscle cell membrane.	Clindamycin	47-58	LOW QUALITY PROTEIN: carbonic anhydrase 2	Cavia porcellus	95-98
33945347-10	2021	Taken together, our results demonstrated that evodiamine enhanced the anti-inflammation effect of clindamycin in the BEAS-2B cells infected with H5N1 and pneumoniae D39 through CREB-C/EBPbeta signaling pathway.	Clindamycin	98-109	cAMP responsive element binding protein 1	Homo sapiens	177-181
29219-3	1978	Multiply resistant Type 19A strains, resistant to beta-lactam antibiotics, erythromycin, clindamycin, tetracycline and chloramphenicol, were isolated from 128 carriers, and were responsible for bacteremia in four patients.	Clindamycin	89-100	SLAM family member 7	Homo sapiens	24-27
4779693-0	1973	Evaluation of clindamycin in group A beta haemolytic streptococcal infections in children.	Clindamycin	14-25	amyloid beta precursor protein	Homo sapiens	35-41
33945347-0	2021	Evodiamine Enhanced the Anti-Inflammation Effect of Clindamycin in the BEAS-2B Cells Infected with H5N1 and Pneumoniae D39 Through CREB-C/EBPbeta Signaling Pathway.	Clindamycin	52-63	cAMP responsive element binding protein 1	Homo sapiens	131-135
33945347-10	2021	Taken together, our results demonstrated that evodiamine enhanced the anti-inflammation effect of clindamycin in the BEAS-2B cells infected with H5N1 and pneumoniae D39 through CREB-C/EBPbeta signaling pathway.	Clindamycin	98-109	CCAAT enhancer binding protein alpha	Homo sapiens	182-191
33945347-0	2021	Evodiamine Enhanced the Anti-Inflammation Effect of Clindamycin in the BEAS-2B Cells Infected with H5N1 and Pneumoniae D39 Through CREB-C/EBPbeta Signaling Pathway.	Clindamycin	52-63	CCAAT enhancer binding protein alpha	Homo sapiens	136-145
33174961-10	2020	Among clindamycin-resistant MRSA, 83%, 17%, 10%, 4%, and 2% carried ermA, ermC, ermB, linA, and linB genes, respectively.	Clindamycin	6-17	ErmC	Staphylococcus aureus	74-78
33659065-0	2021	In-hospital mortality among patients with invasive non-group A beta-hemolytic Streptococcus treated with clindamycin combination therapy: a nationwide cohort study.	Clindamycin	105-116	amyloid beta precursor protein	Homo sapiens	61-67
31857248-5	2020	TP1 exhibited resistance to aminoglycosides (gentamicin and amikacin), macrolides (erythromycin), lincosamides (clindamycin), sulfonamides (sulfamonomethoxine), tetracyclines (tetracycline and doxycycline) and chloramphenicols (chloramphenicol and florfenicol).	Clindamycin	112-123	transition protein 1	Bos taurus	0-3
31768707-0	2020	Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-alpha and CXCL-1 production and activating opioidergic mechanisms.	Clindamycin	0-11	tumor necrosis factor	Mus musculus	54-81
31768707-0	2020	Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-alpha and CXCL-1 production and activating opioidergic mechanisms.	Clindamycin	0-11	chemokine (C-X-C motif) ligand 1	Mus musculus	86-92
31768707-15	2020	CFA-induced production of TNF-alpha and CXCL-1 was reduced by clindamycin (400 mg/kg, i.p.).	Clindamycin	62-73	tumor necrosis factor	Mus musculus	26-35
31768707-15	2020	CFA-induced production of TNF-alpha and CXCL-1 was reduced by clindamycin (400 mg/kg, i.p.).	Clindamycin	62-73	chemokine (C-X-C motif) ligand 1	Mus musculus	40-46
31853613-7	2020	Moreover, DOX provoked inflammatory responses in renal tissues as confirmed by increased expressions of NF-kappaB and COX-2 which were significantly reduced by clindamycin pretreatment.	Clindamycin	160-171	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	118-123
31531048-3	2019	The maximum adsorption capacities of AMP and CLI on GO nanosheets were found to be 33.33 mg g-1 and 47 mg g-1, respectively.	Clindamycin	45-48	proline rich protein BstNI subfamily 3	Homo sapiens	92-109
29947262-3	2020	In this study, the effects of the antibiotics, furosemide, cefazolin, cefuroxime, gentamicin and clindamycin on rat erythrocyte G6PD enzyme was studied in in vitro conditions.	Clindamycin	97-108	glucose-6-phosphate dehydrogenase	Rattus norvegicus	128-132
29947262-6	2020	The inhibition studies of these antibiotics were carried out on the enzyme revealing that gentamicin, clindamycin and furosemide inhibited the activity of the G6PD with an IC50 of 1.75, 34.65 and 0.526 mM, respectively with Ki of 0.7, 39.8 and 0.860 mM, respectively.	Clindamycin	102-113	glucose-6-phosphate dehydrogenase	Rattus norvegicus	159-163
31597722-13	2019	The reduction in TSST-1 production and lesion size after a single dose of clindamycin underscores a potential role for adjunctive clindamycin at the start of treatment of patients suspected of having TSS to alter disease progression.IMPORTANCE Staphylococcal toxic shock syndrome (TSS) is a life-threatening illness causing fever, rash, and shock, attributed to toxins produced by the bacterium Staphylococcus aureus, mainly toxic shock syndrome toxin 1 (TSST-1).	Clindamycin	74-85	AT695_RS01930	Staphylococcus aureus	362-367
31063788-2	2019	In this study, the effect of aminoglycosides (AGs: streptomycin, gentamycin, lincomycin and clindamycin) on interactions between bovine serum albumin (BSA) was evaluated employing imaging and probing adhesion event by AFM.	Clindamycin	92-103	albumin	Homo sapiens	136-149
31013627-8	2019	Efflux ratios of P-gp substrates (tilmicosin, ciprofloxacin, clindamycin, ampicillin, and enrofloxacin) decreased and the apparent permeability coefficients increased after co-incubation with berberine in MDCK-chAbcb1 cell models.	Clindamycin	61-72	phosphoglycolate phosphatase	Gallus gallus	17-21
30262964-4	2018	Erythromycin/clindamycin-resistant staphylococci carried lnuA/lnuB genes frequently alone or combined with msrA gene.	Clindamycin	13-24	ABC transporter permease protein	Staphylococcus aureus	107-111
30413232-7	2018	He was initially treated with 2 weeks of clindamycin 300 mg twice daily (bid) without improvement.	Clindamycin	41-52	BH3 interacting domain death agonist	Homo sapiens	73-76